{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T09:00:17Z","timestamp":1781082017406,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13300-026-01856-6","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:26:29Z","timestamp":1776227189000},"page":"807-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Podcast Episode\u00a02: Heart Failure Management in Patients with Diabetes for Endocrinologists, Primary Care Physicians, and Noncardiologist Clinicians: Focus on SGLT2 Inhibitors"],"prefix":"10.1007","volume":"17","author":[{"given":"Nihar R.","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Eugene E.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"issue":"24","key":"1856_CR1","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","volume":"106","author":"DM Lloyd-Jones","year":"2002","unstructured":"Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068\u201372.","journal-title":"Circulation"},{"issue":"17","key":"1856_CR2","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;79(17):e263\u2013421.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"1856_CR3","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.jacc.2018.08.2160","volume":"72","author":"M Aggarwal","year":"2018","unstructured":"Aggarwal M, Bozkurt B, Panjrath G, et al. Lifestyle modifications for preventing and treating heart failure. J Am Coll Cardiol. 2018;72(19):2391\u2013405.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1856_CR4","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.jhh.1001459","volume":"16","author":"FJ He","year":"2002","unstructured":"He FJ, MacGregor GA. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens. 2002;16(11):761\u201370.","journal-title":"J Hum Hypertens."},{"issue":"7","key":"1856_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1311989","volume":"371","author":"A Mente","year":"2014","unstructured":"Mente A, O\u2019Donnell MJ, Rangarajan S, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371(7):601\u201311.","journal-title":"N Engl J Med"},{"issue":"1","key":"1856_CR6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/MOL.0000000000000033","volume":"25","author":"PK Whelton","year":"2014","unstructured":"Whelton PK, He J. Health effects of sodium and potassium in humans. Curr Opin Lipidol. 2014;25(1):75\u20139.","journal-title":"Curr Opin Lipidol"},{"issue":"12","key":"1856_CR7","volume":"14","author":"EO Evbayekha","year":"2022","unstructured":"Evbayekha EO, Aiwuyo HO, Dilibe A, et al. Sleep deprivation is associated with increased risk for hypertensive heart disease: a nationwide population-based cohort study. Cureus. 2022;14(12):e33005.","journal-title":"Cureus"},{"issue":"1","key":"1856_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2018-000604","volume":"6","author":"SL Erin","year":"2018","unstructured":"Erin SL, Ning XS, Gregory AN, Michael JA, Gregory NC. Insomnia is associated with an increased risk of type 2 diabetes in the clinical setting. BMJ Open Diabetes Res Care. 2018;6(1):e000604.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"11","key":"1856_CR9","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11892-016-0805-8","volume":"16","author":"MA Grandner","year":"2016","unstructured":"Grandner MA, Seixas A, Shetty S, Shenoy S. Sleep duration and diabetes risk: population trends and potential mechanisms. Curr Diab Rep. 2016;16(11):106.","journal-title":"Curr Diab Rep"},{"issue":"6","key":"1856_CR10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.4037\/ajcc2016219","volume":"25","author":"KS Lee","year":"2016","unstructured":"Lee KS, Lennie TA, Heo S, Song EK, Moser DK. Prognostic importance of sleep quality in patients with heart failure. Am J Crit Care. 2016;25(6):516\u201325.","journal-title":"Am J Crit Care"},{"issue":"10","key":"1856_CR11","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0800-z","volume":"21","author":"MMY Lee","year":"2019","unstructured":"Lee MMY, Sattar N, McMurray JJV, Packard CJ. Statins in the prevention and treatment of heart failure: a review of the evidence. Curr Atheroscler Rep. 2019;21(10):41.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"1856_CR12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1001\/jamacardio.2019.3665","volume":"4","author":"MB Mortensen","year":"2019","unstructured":"Mortensen MB, Nordestgaard BG. Statin use in primary prevention of atherosclerotic cardiovascular disease according to 5 major guidelines for sensitivity, specificity, and number needed to treat. JAMA Cardiol. 2019;4(11):1131\u20138.","journal-title":"JAMA Cardiol"},{"issue":"23","key":"1856_CR13","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1136\/heartjnl-2016-310794","volume":"103","author":"C Tuegel","year":"2017","unstructured":"Tuegel C, Bansal N. Heart failure in patients with kidney disease. Heart. 2017;103(23):1848\u201353.","journal-title":"Heart"},{"issue":"22","key":"1856_CR14","doi-asserted-by":"publisher","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","volume":"103","author":"C Iribarren","year":"2001","unstructured":"Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients\u00a0with\u00a0diabetes. Circulation. 2001;103(22):2668\u201373.","journal-title":"Circulation"},{"issue":"7258","key":"1856_CR15","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"12","key":"1856_CR16","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1007\/s00125-008-1164-z","volume":"51","author":"A Pazin-Filho","year":"2008","unstructured":"Pazin-Filho A, Kottgen A, Bertoni AG, et al. HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia. 2008;51(12):2197\u2013204.","journal-title":"Diabetologia"},{"issue":"Supplement_1","key":"1856_CR17","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR, et al. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142023. Diabetes Care. 2022;46(Supplement_1):S140\u201357.","journal-title":"Diabetes Care"},{"key":"1856_CR18","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes; 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes\u20142026. Diabetes Care. 2026;49(Supplement_1):S216\u2013S245.","DOI":"10.2337\/dc26-S010"},{"issue":"5","key":"1856_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1111\/dom.13645","volume":"21","author":"DK McGuire","year":"2019","unstructured":"McGuire DK, Marx N, Johansen OE, Inzucchi SE, Rosenstock J, George JT. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: one decade later. Diabetes Obes Metab. 2019;21(5):1073\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"1856_CR20","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"1856_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"1856_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"15","key":"1856_CR23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"21","key":"1856_CR24","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"1856_CR25","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"16","key":"1856_CR26","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"1856_CR27","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"22","key":"1856_CR28","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1161\/CIRCULATIONAHA.119.040057","volume":"139","author":"GA Figtree","year":"2019","unstructured":"Figtree GA, Radholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation. 2019;139(22):2591\u20133.","journal-title":"Circulation"},{"issue":"4","key":"1856_CR29","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313.","journal-title":"Nat Med"},{"issue":"3","key":"1856_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374.","journal-title":"Nat Med"},{"issue":"4","key":"1856_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jama.2012.216476","volume":"309","author":"K Dharmarajan","year":"2013","unstructured":"Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013;309(4):355\u201363.","journal-title":"JAMA"},{"issue":"13","key":"1856_CR32","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1161\/CIRCULATIONAHA.107.696906","volume":"116","author":"SD Solomon","year":"2007","unstructured":"Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482\u20137.","journal-title":"Circulation"},{"issue":"3","key":"1856_CR33","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/ehf2.13296","volume":"8","author":"K Lindmark","year":"2021","unstructured":"Lindmark K, Boman K, St\u00e5lhammar J, et al. Recurrent heart failure hospitalizations increase the risk of cardiovascular and all-cause mortality in patients with heart failure in Sweden: a real-world study. ESC Heart Fail. 2021;8(3):2144\u201353.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"1856_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10741-021-10097-7","volume":"27","author":"H Clark","year":"2022","unstructured":"Clark H, Rana R, Gow J, Pearson M, van der Touw T, Smart N. Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review. Heart Fail Rev. 2022;27(2):559\u201372.","journal-title":"Heart Fail Rev"},{"issue":"8","key":"1856_CR35","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jchf.2024.04.003","volume":"12","author":"V Kittipibul","year":"2024","unstructured":"Kittipibul V, Vaduganathan M, Ikeaba U, et al. Cause-specific health care costs following hospitalization for heart failure and cost offset with SGLT2i therapy. JACC Heart Fail. 2024;12(8):1409\u201321.","journal-title":"JACC Heart Fail"},{"issue":"10458","key":"1856_CR36","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/S0140-6736(24)01733-1","volume":"404","author":"PS Jhund","year":"2024","unstructured":"Jhund PS, Talebi A, Henderson AD, et al. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis. Lancet. 2024;404(10458):1119\u201331.","journal-title":"Lancet"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01856-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01856-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:23:00Z","timestamp":1781079780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-026-01856-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1856"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01856-6","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"11 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nihar R. Desai: research grants and consulting for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cytokinetics, Merck, Novartis, SCPharmaceuticals, and Vifor. Silvio E. Inzucchi: has served as a consultant or on clinical trial committees or advisory boards for AstraZeneca, Bayer,\u00a0Boehringer Ingelheim,\u00a0Corcept,\u00a0Merck,\u00a0Novo Nordisk, and\u00a0Pfizer; and has delivered lectures sponsored by AstraZeneca and\u00a0Boehringer Ingelheim. Eugene E. Wright Jr: has participated in speaker bureaus for Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, and Sanofi. He has served as a consultant\/advisory board member for: Abbott Diabetes Care, Bayer, Boehringer Ingelheim, Eli Lilly, Embecta, Medtronic, and\u00a0Sanofi. He also reports honorarium and writing support from Springer Health; advisor for Ascensia; content reviewer for UpToDate; and Clinical Diabetes Associate Editor for American Diabetes Association Publications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}